Lantheus Holdings, Inc. LNTH is scheduled to launch third-quarter 2023 outcomes on Nov 2, earlier than the opening bell.
In the final reported quarter, Lantheus earnings per share (EPS) of $1.54 surpassed the Zacks Consensus Estimate by 15.8%. Over the trailing 4 quarters, its earnings outperformed the Zacks Consensus Estimate on all events, the common being 22.9%.
Let’s see how issues have formed up previous to this announcement.
Factors at Play
On second-quarter 2023 earnings name in August, Lantheus’ administration confirmed that it has been persevering with to register a strong uptick in gross sales of each PYLARIFY and DEFINITY. Per administration, they proceed to have the main market share of their respective classes.
The continued favorable adoption of PSMA PET with PYLARIFY is predicted to have continued within the third quarter of 2023 on the again of its optimistic impression of the PSMA-targeted PET imaging on the U.S. prostate most cancers neighborhood. This is more likely to have significantly pushed the third-quarter revenues.
Lantheus Holdings, Inc. Price and EPS Surprise
Lantheus Holdings, Inc. price-eps-surprise | Lantheus Holdings, Inc. Quote
It is price mentioning that PYLARIFY is an F 18-labelled PSMA-targeted positron emission tomography (PET) imaging agent used with PET or computed tomography, whereas DEFINITY is an injectable ultrasound-enhancing agent utilized in echocardiography examinations. Management additionally expects its F-18 labeled PET diagnostic imaging agent focusing on tau-tangles for Alzheimer’s illness, MK-6240, to have maintained its momentum within the to-be-reported quarter.
On the second-quarter earnings name, administration’s assertion that DEFINITY maintained its robust momentum with robust second-quarter gross sales was encouraging. Management believed that a rise in general well being system process quantity as sufferers’ visits continued to rebound within the post-pandemic setting contributed to year-over-year progress. Management expects these traits, mixed with its sustained deal with academic applications and promotional efforts, to assist maintain Lantheus’ momentum within the second half of the yr. This appears promising for the corporate’s third-quarter outcomes.
Lantheus’ Precision Diagnostics product class (which incorporates business merchandise like DEFINITY and TechneLite, amongst others) had recorded sturdy gross sales within the second quarter of 2023. This was primarily pushed by energy in DEFINITY and TechneLite (primarily ensuing from the belief of opportunistic gross sales within the quarter). This momentum is more likely to have continued within the to-be-reported quarter, thus considerably driving up the revenues.
On the second-quarter earnings name, administration acknowledged that Lantheus has been working intently with its accomplice, POINT Biopharma, to make progress with respect to PNT2002 throughout analysis and improvement, provide chain, manufacturing and business readiness. These developments buoy our optimism about Lantheus’ third-quarter efficiency.
On the second-quarter earnings name, Lantheus’ administration acknowledged that its PSMA PET imaging agent will quickly be available to prostate most cancers sufferers in Europe. Its European accomplice, Curium, introduced in July that they’ve obtained advertising authorization from the European Commission. We count on the corporate to supply extra particulars through the third-quarter earnings name.
The Estimate Picture
Per our confirmed mannequin, a inventory with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), together with a optimistic Earnings ESP, has larger possibilities of beating estimates. This isn’t the case right here, as you possibly can see beneath.
Earnings ESP: Lantheus has an Earnings ESP of 0.00%. You can uncover the most effective shares to purchase or promote earlier than they’re reported with our Earnings ESP Filter.
Zacks Rank: The firm at present carries a Zacks Rank #4 (Sell).
Stocks Worth a Look
Here are just a few different medical shares price contemplating, as these even have the best mixture of components to beat on earnings this reporting cycle.
Insulet Corporation PODD has an Earnings ESP of +6.61% and a Zacks Rank of two. PODD has an estimated long-term progress charge of 41.5%. You can see the entire listing of in the present day’s Zacks #1 Rank shares right here.
Insulet’s earnings surpassed estimates in all of the trailing 4 quarters, with the common shock being 126.9%.
Shockwave Medical, Inc. SWAV has an Earnings ESP of +6.07% and is a Zacks #1 Rank inventory. SWAV has an estimated long-term progress charge of 4.6%.
Shockwave Medical’s earnings surpassed estimates in three of the trailing 4 quarters and missed as soon as, with the common shock being 81.1%.
Monte Rosa Therapeutics, Inc. GLUE has an Earnings ESP of +1.33% and a Zacks Rank of two. GLUE has a progress charge of 1.4% for 2024.
Monte Rosa’s earnings surpassed estimates in all of the trailing 4 quarters, with the common shock being 3.8%.
Stay on prime of upcoming earnings bulletins with the Zacks Earnings Calendar.
Want the latest suggestions from Zacks Investment Research? Today, you possibly can obtain 7 Best Stocks for the Next 30 Days. Click to get this free report
Insulet Corporation (PODD) : Free Stock Analysis Report
Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report
ShockWave Medical, Inc. (SWAV) : Free Stock Analysis Report
Monte Rosa Therapeutics, Inc. (GLUE) : Free Stock Analysis Report
